ABCAM PLC Directorate Change (3922K)

TIDMABC

RNS Number : 3922K

ABCAM PLC

13 December 2018

For immediate release

13 December 2018

ABCAM PLC

Appointment of Non-Executive Director

Abcam plc ("Abcam" or "the Company", AIM: ABC), a global leader in the supply of life science research tools, is pleased to announce the appointment of Giles Kerr as a non-executive Director with effect from 12 December 2018.

Giles has extensive experience as an executive and non-executive Director in a wide range of public and private organisations. He recently stepped down as Finance Director of Oxford University, a position he had held since 2005. He remains a non-executive Director of Arix Biosciences plc, Adaptimmune Therapeutics plc, Senior plc, PayPoint plc as well as Oxford Sciences Innovation. From 1990 to 2004 Giles held a number of roles at Amersham plc, including Group Finance Director. Giles is a graduate in Economics from the University of York and a Chartered Accountant.

Peter Allen, Chairman of Abcam said: "I am delighted Giles is joining the Board of Abcam. Giles brings a wealth of experience within the life science sector, finance and a first-hand understanding of our academic research customers. He will make a valuable contribution to our Board."

Giles Kerr commented: "I have known and admired Abcam's business for many years and am proud to be able to join the team. I look forward to working with the Board as the Company continues to execute on its strategy and build on its position as global leader."

Giles will join the Audit & Risk Committee.

The composition of each of the Board Committees has also been amended and is confirmed as follows:

 
 Board Committee            Membership 
 Nomination Committee       Peter Allen (Chairman) 
                             Louise Patten 
                             Sue Harris 
                             Mara Aspinall 
                           ========================= 
 Remuneration Committee     Louise Patten (Chairman) 
                             Peter Allen 
                             Sue Harris 
                             Mara Aspinall 
                           ========================= 
 Audit and Risk Committee   Sue Harris (Chairman) 
                             Peter Allen 
                             Louise Patten 
                             Giles Kerr 
                           ========================= 
 

AIM Rules disclosures

Giles (age 59) holds or has held directorships in the five years preceding his appointment at Abcam as follows:

 
 Current directorships          Previous Directorships 
 Arix Bioscience plc            BTG plc 
                               ============================= 
 PayPoint plc                   Quanta Dialysis Technologies 
                               ============================= 
 Adaptimmune Therapeutics plc   Victrex plc 
                               ============================= 
 Senior plc                     Elan Corporation 
                               ============================= 
 Oxford Sciences Innovation 
                               ============================= 
 

Save as disclosed above there are no additional disclosures to be made in accordance with Schedule Two paragraph (g) of the AIM Rules.

For further information, please contact:

Abcam

+ 44 (0) 1223 696 000

Suzanne Smith, Chief Legal Officer and Company Secretary

James Staveley, VP, Investor Relations

J.P.Morgan Cazenove - Nominated Advisor & Corporate Broker

+ 44 (0) 20 7742 4000

James Mitford

FTI Consulting

+ 44 (0) 20 3727 1000

Ben Atwell / Brett Pollard / Natalie Garland-Collins

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the c.56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Abcam's eleven locations are in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 130 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com and www.abcamplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOAGMMMZGFFGRZM

(END) Dow Jones Newswires

December 13, 2018 05:06 ET (10:06 GMT)